Please login to the form below

Not currently logged in
Email:
Password:

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

ImmunoCellular Andre GengosCancer specialist ImmunoCellular Therapeutics has appointed Andrew Gengos as president and CEO.

Gengos joins from Neuraltus Pharmaceuticals, where he also served as president and CEO, and becomes the permanent replacement for Dr Manish Singh who left the company in August 2012 to "pursue other opportunities".

Since August, ImmunoCellular's founder and chief scientific officer Dr John Yo has served as interim CEO.

Gengos joins at an important time for ImmunoCellular, with the company having recently commenced a phase II trial investigating its lead product candidate ICT-107, a potential cell-based vaccine for glioblastoma brain tumours.

ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

“Joining ImmunoCellular is an extraordinary opportunity to help build a leading biopharmaceutical company with the potential to transform the treatment of cancer,” said Gengos. “I believe that the company's immunotherapy platform that targets both cancer cells and cancer stem cells represents a promising and innovative medical breakthrough.”

Prior to joining Neuraltus spent more than seven years at Amgen, holding such positions as VP, strategy and corporate development.

He has also spent time at Dynavax Technologies, Chiron Corporation and McKinsey & Company.

5th December 2012

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....